Global provider continues to expand analytical service
capabilities for life science companies developing advanced
treatments for cancer and rare diseases
KAISERAUGST, Switzerland, May 6, 2024
/PRNewswire/ -- Solvias announced today that it is expanding its
global network of laboratory testing centers with a new biotech
site in Research Triangle Park,
N.C. It is the company's latest investment to expand its
analytical testing services supporting life science organizations
with the growing number of cell and gene therapies (CGTs) and
biologics in use and under development.
The 50,000-square-foot facility, expected to be completed in
2025 and bring 170+ jobs to the Raleigh-Durham area, will serve as Solvias'
North American hub for large molecule analytical services. It will
offer critical cell-based potency assays, advanced Next-Gen
Sequencing (NGS) capabilities, and related testing services
supporting multiple biologic modalities. From the outset, the new
testing center will support characterization and release testing of
CGT and other advanced therapies, including Adeno-Associated
virus (AAV) gene therapies, mRNA therapies and antibody drug
conjugates.
Noting that the global CGT and advanced biologics market is
expected to maintain a double-digit annual growth rate over the
next ten years, Archie Cullen, CEO
of Solvias, said: "Our new center strongly complements our
biologics and CGT sites in Europe
and expands our world-class testing capabilities in the U.S. Our
team is thrilled to bring our newest center of excellence to
Research Triangle Park, a leading
research and development center and burgeoning hub for the life
science industry. We will continue to invest in expanding our
capabilities to support our customers with their critical work of
developing and maintaining life-changing therapies."
Solvias' new facility expands its global footprint to six
centers of excellence. It is the company's second site in the U.S.,
where it supports life science organizations with analytical
testing. The new center will feature state-of-the-art analytical
instrumentation, laboratory automation technology and integrated
digital management systems.
About Solvias
Solvias is a global provider of chemistry, manufacturing, and
control (CMC) analytics to the life science industry. Its team of
scientists combine years of experience with regulatory
understanding across small molecules, biologics, and cell and gene
therapies. The company offers comprehensive solutions from raw
materials to drug products to final release testing, as well as API
development and manufacturing for small molecules. Headquartered
near Basel, Switzerland, Solvias
operates five global centers of excellence to the highest standards
and in accordance with ISO, GMP, GLP and FDA regulations. For more
information, visit solvias.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/solvias-to-build-biologics-and-cell--gene-therapy-testing-center-in-research-triangle-park-302135596.html
SOURCE Solvias